Experienced in Hodgkin Lymphoma

Mark Basik

Montreal, QC, CA 
Experienced in Hodgkin Lymphoma
Montreal, QC, CA 
OverviewLocationsClinical Research

Overview

Mark Basik practices in Montreal, Canada. Mr. Basik is rated as an Experienced expert by MediFind in the treatment of Hodgkin Lymphoma. His top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, HER-2 Positive Breast Cancer, Mastectomy, and Tissue Biopsy.

His clinical research consists of co-authoring 120 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Hodgkin Lymphoma.

Gender
Male

Locations

Montreal, QC, Canada
Other Locations
Canada
Quebec, QC H4A3T2, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Early Detection of Cancer in High-risk Patients Through Cell-free DNA
Early Detection of Cancer in High-risk Patients Through Cell-free DNA
Enrollment Status: Active_not_recruiting
Publish Date: December 16, 2025
Intervention Type: Genetic
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients With Clinical/Radiologic Complete Response After Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment Without Surgery
A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients With Clinical/Radiologic Complete Response After Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment Without Surgery
Enrollment Status: Completed
Publish Date: May 22, 2025
Intervention Type: Procedure
Study Phase: Phase 2
A Large-scale Longitudinal Oncology Registry
A Large-scale Longitudinal Oncology Registry
Enrollment Status: Suspended
Publish Date: February 04, 2025
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
Prospective Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients
Prospective Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients
Enrollment Status: Completed
Publish Date: June 02, 2022
Intervention Type: Procedure
View 6 Less Clinical Trials

120 Total Publications

ASO Visual Abstract: Uptake of Risk Reducing Mastectomy in Older BRCA1/2 and PALB2 Carriers Undergoing Genetic Testing After 60 Years of Age.
ASO Visual Abstract: Uptake of Risk Reducing Mastectomy in Older BRCA1/2 and PALB2 Carriers Undergoing Genetic Testing After 60 Years of Age.
Journal: Annals of surgical oncology
Published: November 10, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Basik's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile